Plexium, Inc.
Plexium is a next-generation targeted protein degradation (TPD) company that discovers Monovalent Direct Degraders and Molecular Glues.
Funding history
About Plexium, Inc.
How much funding has Plexium, Inc. raised?
Plexium, Inc. has raised $60.1M in total funding. The most recent round was Series B.
Where is Plexium, Inc. headquartered?
Plexium, Inc. is headquartered in San Diego, CA.
What does Plexium, Inc. do?
Plexium is a next-generation targeted protein degradation (TPD) company that discovers Monovalent Direct Degraders and Molecular Glues.
What problem does Plexium, Inc. solve?
High unmet medical needs exist for patients where current treatments fall short, particularly where disease-causing proteins have been considered undruggable.
What's Plexium, Inc.'s solution?
Plexium rationally designs and discovers monovalent direct degraders and molecular glues, small molecule compounds meant to be developed as targeted protein degradation therapeutics.
What makes Plexium, Inc. different?
Their pipeline runs on the proprietary DELTA Discovery platform, including an ultra-high throughput cell-based screening capability that has already advanced multiple clinical-stage protein degraders.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.